Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma

Rhea-AI Summary

Nuvation Bio (NYSE: NUVB) announced that the U.S. FDA has granted Fast Track Designation for safusidenib, its investigational oral, brain-penetrant selective inhibitor of mutant IDH1, for the treatment of IDH1-mutant glioma.

According to Nuvation Bio, Fast Track status is intended to facilitate development and expedite review for serious conditions with unmet medical need and may allow more frequent FDA interactions and rolling review of a marketing application, potentially shortening time to patients if future data are positive.

The designation was granted based on favorable data from the safusidenib program, including updated Phase 2 J201 results: at a median follow-up of 38.8 months, treatment showed a confirmed objective response rate of 51.9%, median progression-free survival not yet reached, and a 36‑month progression-free survival rate of 79.1%, with no new safety signals identified.

Safusidenib is being further evaluated in the pivotal Phase 3 SIGMA (G203) study in IDH1-mutant astrocytoma with high-risk features (approximately 300 patients) and in additional Phase 2 and Phase 3 studies, including settings where there are limited or no approved targeted options.

Positive

• FDA Fast Track Designation granted for safusidenib in IDH1-mutant glioma
• Phase 2 J201 study cORR of 51.9% at 38.8-month median follow-up
• 36-month progression-free survival rate of 79.1% with median PFS not reached
• No new safety signals observed with longer-term safusidenib follow-up
• Pivotal Phase 3 SIGMA trial enrolling ~300 IDH1-mutant astrocytoma patients
• Exploratory oligodendroglioma cohort targeting ~40 additional patients

Negative

• None.

Market Context

Tag-matched clinical-trial events recorded an average move of 7.64% across 5 events. That history co...

Analysis

Tag-matched clinical-trial events recorded an average move of 7.64% across 5 events. That history contextualizes the Fast Track designation, while Net Selling insider activity is a risk factor; SIGMA enrollment and clinical confirmation remain key watchpoints.

Key Figures

Median follow-up: 38.8 months Confirmed objective response rate: 51.9% 36-month PFS rate: 79.1% +5 more

8 metrics

Median follow-up 38.8 months Phase 2 J201 study

Confirmed objective response rate 51.9% Phase 2 J201 study

36-month PFS rate 79.1% Phase 2 J201 study

Patients with subsequent progression 1 patient Previously responded patients in J201

Annual U.S. diagnoses Nearly 2,500 people IDH-mutant gliomas

IDH1 mutation prevalence More than 95% U.S. IDH-mutant glioma diagnoses

Pivotal cohort enrollment Approximately 300 patients Phase 3 SIGMA study

Exploratory cohort enrollment Approximately 40 patients Grade 3 IDH1-mutant oligodendroglioma cohort

Previous Clinical trial Reports

5 past events · Latest: Jul 20 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 20	Phase 2 data	Positive	+7.9%	Updated safusidenib data and expansion of two additional clinical studies
May 06	FDA filing acceptance	Positive	+4.3%	FDA accepted IBTROZI supplemental application with updated duration-of-response data
Feb 09	Phase 3 trial	Positive	-1.1%	SIGMA converted to pivotal Phase 3 with expanded enrollment and exploratory cohort
Dec 03	Phase 2 publication	Positive	+12.1%	Published positive safusidenib results with response and progression-free survival data
Sep 30	Phase 3 enrollment	Positive	+14.9%	First patient enrolled in adjuvant IBTROZI Phase 3 study

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Tag-matched clinical-trial news was usually followed by gains, although the February Phase 3 SIGMA announcement diverged with a decline.

Key Terms

fast track designation, objective response rate, progression-free survival, rolling review, +1 more

5 terms

fast track designation regulatory

"FDA has granted Fast Track Designation for safusidenib"

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

objective response rate medical

"showed a confirmed objective response rate (cORR) of 51.9%"

The objective response rate (ORR) is the percentage of patients in a clinical trial whose tumors measurably shrink or disappear according to preset rules. Investors use it as a quick, objective signal of a drug’s ability to produce a clear treatment effect—like counting how many plants visibly respond after applying a new fertilizer—and higher ORR can improve odds of regulatory approval, commercial success, and company valuation.

progression-free survival medical

"with median progression-free survival (PFS) not yet reached"

Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.

rolling review regulatory

"the designation may allow for rolling review of a marketing application"

A rolling review is a regulatory process where health authorities examine data on a drug or vaccine as it becomes available instead of waiting for a complete file at the end. For investors, this can speed up the timeline to approval and reduce uncertainty because regulators assess progress in real time—think of reading and approving chapters of a book as they’re finished rather than waiting for the whole manuscript, which can bring forward potential market access and revenue.

brain-penetrant medical

"the company's investigational, oral, brain-penetrant selective inhibitor"

A brain-penetrant drug or molecule can cross the brain’s natural security gate (the blood–brain barrier) to reach and act on cells inside the brain. For investors, that matters because treatments that reach the brain can address disorders like Alzheimer’s, depression, or brain cancer—opening large markets—but they also carry higher technical risk, stricter safety testing and unique regulatory challenges compared with drugs that act elsewhere in the body.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Designation offers pathway to expedite regulatory review, pending positive data, and reinforces safusidenib's potential to address significant medical needs for patients with IDH1-mutant glioma

Pivotal Phase 3 SIGMA study enrollment underway

NEW YORK, Aug. 20, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for safusidenib, the company's investigational, oral, brain-penetrant selective inhibitor of mutant IDH1.

"People with IDH1-mutant glioma urgently need additional treatment options. We were eager to pursue Fast Track Designation for safusidenib to hopefully reach these patients on an expedited timeline," said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio. "We look forward to working with the FDA as we advance our mission to provide an effective therapy to nearly every patient whose life is impacted by this disease."

FDA Fast Track Designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and address unmet medical need. The designation provides for more frequent interactions with the FDA throughout a drug's development. If relevant criteria are met, the designation may allow for rolling review of a marketing application, permitting completed sections to be submitted for FDA review as they become available, rather than waiting for the entire application to be complete. These benefits have the potential to shorten the time it takes to bring safusidenib to patients.

The designation was granted based on favorable data from the safusidenib clinical program to date. Most recently, Nuvation Bio announced updated data from the Phase 2 J201 study demonstrating durable responses and a favorable risk-benefit profile over long-term follow-up. Specifically, at a median follow-up of 38.8 months in the J201 study, treatment with safusidenib showed a confirmed objective response rate (cORR) of 51.9%, with median progression-free survival (PFS) not yet reached and a 36-month PFS rate of 79.1%, and only one patient who had previously responded experienced subsequent disease progression. No new safety signals have been identified with longer-term follow-up. These results build upon findings previously published in Neuro-Oncology.

About IDH1-mutant Glioma
Gliomas are the most common type of brain cancer in adults worldwide. In the U.S., nearly 2,500 people are diagnosed with IDH-mutant gliomas each year, of which more than 95% harbor a mutation in the IDH1 gene. Most patients are diagnosed in their 30s and 40s. While patients with IDH1 mutations generally have longer survival times than those with wild-type IDH1, gliomas are not currently curable and prognosis worsens for those with high-risk features, including high grade tumors.

About Safusidenib
Safusidenib is an investigational, oral, brain-penetrant, selective inhibitor of mutant IDH1. It is being studied in patient populations with significant unmet medical need, including settings where there are limited or no approved targeted treatment options. In Phase 1 and Phase 2 clinical studies, safusidenib demonstrated encouraging clinical activity, including delayed disease progression and durable responses across a range of tumor grades and risk groups, with a favorable risk-benefit profile. These early findings support further investigation of safusidenib in the currently enrolling Phase 3 SIGMA study, as well as in the Phase 3 G307 study outside the U.S. where vorasidenib is not yet approved or accessible and the Phase 2 G209 study in a post-vorasidenib setting.

In August 2026, the FDA granted Fast Track Designation to safusidenib in IDH1-mutant glioma.

About the SIGMA (G203) Study
SIGMA is a pivotal Phase 3 study that will evaluate safusidenib compared to placebo as a maintenance therapy after standard-of-care in IDH1-mutant astrocytoma with high-risk features. The pivotal portion of the study will enroll approximately 300 patients.

A separate, exploratory, non-pivotal cohort will evaluate safusidenib in participants with grade 3 IDH1-mutant oligodendroglioma who have not yet received chemotherapy or radiotherapy. The primary endpoint is objective response rate. This cohort is expected to enroll approximately 40 patients.

About Nuvation Bio
Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients' lives. Our diverse pipeline includes taletrectinib (IBTROZI^®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program.

Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, visit www.nuvationbio.com or follow the company on LinkedIn and X (@nuvationbioinc). 

Forward-Looking Statements
Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding safusidenib's therapeutic potential and our hope that FDA's Fast Track designation for safusidenib may allow for expedited regulatory review if relevant criteria are met. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management team of Nuvation Bio and are not predictions of actual performance. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ from those anticipated by the forward-looking statements, including but not limited to the challenges associated with conducting drug discovery and commercialization, and initiating or conducting clinical studies due to, among other things, difficulties or delays in the regulatory process, enrolling subjects or manufacturing or acquiring necessary products; the emergence or worsening of adverse events or other undesirable side effects; risks associated with preliminary and interim data, which may not be representative of more mature data; physician and patient behavior; and competitive developments. Risks and uncertainties facing Nuvation Bio are described more fully in its Form 10-Q filed with the SEC on August 6, 2026, under the heading "Risk Factors," and other documents that Nuvation Bio has filed or will file with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Nuvation Bio disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release.

Nuvation Bio Investor Contact
JR DeVita
ir@nuvationbio.com

Nuvation Bio Media Contact
Kaitlyn Nealy
media@nuvationbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvation-bio-granted-fda-fast-track-designation-for-safusidenib-for-treatment-of-idh1-mutant-glioma-302855678.html

SOURCE Nuvation Bio Inc.

FAQ

What did the FDA grant to Nuvation Bio (NUVB) for safusidenib in August 2026?

The FDA granted Fast Track Designation to safusidenib for treating IDH1-mutant glioma in August 2026. According to Nuvation Bio, this status is intended to facilitate development and potentially expedite regulatory review for therapies addressing serious conditions with unmet medical need.

Why is FDA Fast Track Designation for safusidenib important for Nuvation Bio (NUVB) investors?

Fast Track may enable more frequent FDA interactions and rolling review, potentially shortening time to market if data support approval. According to Nuvation Bio, these regulatory advantages could accelerate safusidenib’s path in IDH1-mutant glioma, a serious cancer with limited targeted treatment options.

What clinical results supported Fast Track Designation for safusidenib in IDH1-mutant glioma?

The designation was granted based on favorable safusidenib data, including updated Phase 2 J201 results. According to Nuvation Bio, at 38.8-month median follow-up, safusidenib showed a 51.9% confirmed objective response rate, 36-month progression-free survival of 79.1%, and no new safety signals.

What is the design of the Phase 3 SIGMA (G203) study for safusidenib?

SIGMA is a pivotal Phase 3 trial comparing safusidenib to placebo as maintenance therapy after standard-of-care in IDH1-mutant astrocytoma with high-risk features. According to Nuvation Bio, the pivotal portion plans to enroll approximately 300 patients to evaluate clinical benefit.

Are there additional safusidenib studies besides the SIGMA Phase 3 trial for NUVB?

Yes. According to Nuvation Bio, safusidenib is also being studied in the Phase 3 G307 trial outside the U.S. where vorasidenib is not yet approved or accessible, and in the Phase 2 G209 study in a post-vorasidenib setting to explore broader clinical utility.

How is safusidenib expected to help patients with IDH1-mutant glioma?

Safusidenib is an investigational, oral, brain-penetrant selective inhibitor of mutant IDH1 being developed for IDH1-mutant glioma. According to Nuvation Bio, early-phase studies have shown encouraging activity with delayed disease progression and durable responses in populations with significant unmet medical need.

What is the exploratory oligodendroglioma cohort in the SIGMA safusidenib program?

Alongside the pivotal cohort, SIGMA includes a non-pivotal exploratory cohort in grade 3 IDH1-mutant oligodendroglioma patients without prior chemo or radiotherapy. According to Nuvation Bio, this group will enroll about 40 participants, with objective response rate as the primary endpoint.